Jay Moyes Sells 22,000 Shares of PBYI in Planned Transaction

Jay Moyes offloaded 22,000 shares of PBYI on June 12, 2026, in a planned sale at $7.22 per share.

Written by EarningsIQ · Published Jun 15, 2026, 9:01 PM EDT · Updated Jun 16, 2026, 1:00 AM EDT

Key Points

Jay Moyes sold 22,000 shares of PBYI for $158,840 on June 12, 2026, in a planned transaction.
PBYI shares traded at $7.33, with a 52-week range between $0 and an unspecified high.
Other funds like BlackRock reduced their PBYI holdings, while American Century increased theirs by 266,209 shares.

Jay Moyes, a notable insider at PBYI, sold 22,000 shares on June 12, 2026, as part of a planned transaction. The shares were sold at an average price of $7.22, totaling $158,840. This sale was executed under a pre-arranged trading plan.

Insider Buying and Selling at Puma Biotechnology, Inc.

Several insiders were active in June 2026. On June 12, Dorval Allison sold 11,610 shares, Brian Stuglik sold 8,100 shares, Adrian Senderowicz sold 27,000 shares, and Troy Edward Wilson sold 10,800 shares, all at $7.20 each, as part of planned transactions. Interestingly, Jay Moyes also bought 27,000 shares on June 11, suggesting a strategic shift in holdings.

Other Institutional Activity in PBYI

Institutional investors have been busy with PBYI shares. Acorn Capital Advisors maintained its position with 4,131,299 shares valued at about $26.4 million. BlackRock, Inc. trimmed its stake by 43,636 shares, ending with 3,598,952 shares worth approximately $23 million. Acadian Asset Management increased its holdings by 16,936 shares, totaling 2,041,759 shares valued at $13 million. Renaissance Technologies reduced its position by 181,400 shares, while American Century Companies boosted its holdings by 266,209 shares, bringing its total to 1,916,346 shares, valued around $12.2 million.

PBYI Stock Snapshot

PBYI shares recently traded at $7.33. The stock has experienced a 52-week low of $0, while the high remains unspecified. Investors are keeping a close watch on its performance, especially with recent insider and institutional activities.

Analysts Set New Price Targets

HC Wainwright & Co. has reiterated its 'buy' rating on PBYI multiple times, with a price target of $7 as of February 28, 2025. TD Cowen maintained a 'hold' rating with a $4 target, while Barclays held a 'sell' rating with a $2 target. The consensus among analysts is mixed, with a variety of ratings reflecting differing views on the stock's potential.

Bottom Line

Jay Moyes' recent sale of PBYI shares, along with other insider activities, highlights the dynamic changes within the company. Investors closely monitor these insider moves for potential insights, though it's important to remember that such transactions can be planned and not necessarily indicative of future performance. Institutional activity also suggests varied confidence levels among major shareholders.